Related references
Note: Only part of the references are listed.American Radium Society Appropriate Use Criteria for Radiation Therapy in Oligometastatic or Oligoprogressive Non-Small Cell Lung Cancer
Arya Amini et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2022)
Use of Multi-Site Radiation Therapy for Systemic Disease Control
Roshal R. Patel et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2021)
Consolidative Use of Radiotherapy to Block (CURB) Oligoprogression ― Interim Analysis of the First Randomized Study of Stereotactic Body Radiotherapy in Patients With Oligoprogressive Metastatic Cancers of the Lung and Breast
C.J. Tsai et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2021)
Increased biologically effective dose (BED) to the primary tumor is associated with improved survival in patients with oligometastatic NSCLC
Ahsan Farooqi et al.
RADIOTHERAPY AND ONCOLOGY (2021)
High-dose irradiation in combination with non-ablative low-dose radiation to treat metastatic disease after progression on immunotherapy: Results of a phase II trial
Roshal R. Patel et al.
RADIOTHERAPY AND ONCOLOGY (2021)
Pulsed Radiation Therapy to Improve Systemic Control of Metastatic Cancer
Kewen He et al.
FRONTIERS IN ONCOLOGY (2021)
Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial
David A. Palma et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Progression-free survival is a suboptimal predictor for overall survival among metastatic solid tumour clinical trials
Dario Pasalic et al.
EUROPEAN JOURNAL OF CANCER (2020)
Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials
Willemijn S M E Theelen et al.
Lancet Respiratory Medicine (2020)
Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial
James Welsh et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study
Daniel R. Gomez et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
Tony S. K. Mok et al.
LANCET (2019)
Pembrolizumab After Completion of Locally Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer: A Phase 2 Trial
Joshua M. Bauml et al.
JAMA ONCOLOGY (2019)
Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation-Related Abscopal Respons
James W. Welsh et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Time to abandon single-site irradiation for inducing abscopal effects
Eric D. Brooks et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Role of Radiation Therapy in Modulation of the Tumor Stroma and Microenvironment
Hari Menon et al.
FRONTIERS IN IMMUNOLOGY (2019)
Safety of Combined Immunotherapy and Thoracic Radiation Therapy: Analysis of 3 Single-Institutional Phase I/II Trials
Vivek Verma et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2018)
Consolidative Local Ablative Therapy Improves the Survival of Patients With Synchronous Oligometastatic NSCLC Harboring EGFR Activating Mutation Treated With First-Line EGFR-TKIs
Qinghua Xu et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer A Phase 2 Randomized Clinical Trial
Puneeth Iyengar et al.
JAMA ONCOLOGY (2018)
Nano-Based Quantification of Circulating Tumor Cells as a Biomarker of Disease Status in Oligometastatic Patients Following Metastases-Directed Radiation Therapy
D. P. Lindsay et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2018)
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer
T. S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity
Claire Vanpouille-Box et al.
NATURE COMMUNICATIONS (2017)
Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach?
Michael B. Bernstein et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
A randomized phase III trial of stereotactic radiosurgery (SRS) versus observation for patients with asymptomatic cerebral oligo-metastases in non-small-cell lung cancer
S. H. Lim et al.
ANNALS OF ONCOLOGY (2015)
Towards a molecular basis of oligometastatic disease: potential role of micro-RNAs
Abhineet Uppal et al.
CLINICAL & EXPERIMENTAL METASTASIS (2014)
An Individual Patient Data Metaanalysis of Outcomes and Prognostic Factors After Treatment of Oligometastatic Non-Small-Cell Lung Cancer
Allison B. Ashworth et al.
CLINICAL LUNG CANCER (2014)
Propensity Scoree-Matched Analysis of Comprehensive Local Therapy for Oligometastatic Non-Small Cell Lung Cancer That Did Not Progress After Front-Line Chemotherapy
Tommy Sheu et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2014)
DESCRIPTIVE ANALYSIS OF OLIGOMETASTATIC LESIONS TREATED WITH CURATIVE-INTENT STEREOTACTIC BODY RADIOTHERAPY
Michael T. Milano et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2008)
Response to radiofrequency ablation of pulmonary tumours: a prospective, intention-to-treat, multicentre clinical trial (the RAPTURE study)
Riccardo Lencioni et al.
LANCET ONCOLOGY (2008)
Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial
DW Andrews et al.
LANCET (2004)
Share Paper
